CA2235625C - Bactericidal/permeability increasing protein (bpi) for treating conditions associated with corneal transplantation - Google Patents

Bactericidal/permeability increasing protein (bpi) for treating conditions associated with corneal transplantation Download PDF

Info

Publication number
CA2235625C
CA2235625C CA002235625A CA2235625A CA2235625C CA 2235625 C CA2235625 C CA 2235625C CA 002235625 A CA002235625 A CA 002235625A CA 2235625 A CA2235625 A CA 2235625A CA 2235625 C CA2235625 C CA 2235625C
Authority
CA
Canada
Prior art keywords
bpi
corneal
protein product
bpi protein
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002235625A
Other languages
English (en)
French (fr)
Other versions
CA2235625A1 (en
Inventor
Patrick J. Scannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Corp filed Critical Xoma Corp
Publication of CA2235625A1 publication Critical patent/CA2235625A1/en
Application granted granted Critical
Publication of CA2235625C publication Critical patent/CA2235625C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002235625A 1995-11-14 1996-11-12 Bactericidal/permeability increasing protein (bpi) for treating conditions associated with corneal transplantation Expired - Fee Related CA2235625C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/557,287 US5686414A (en) 1995-11-14 1995-11-14 Methods of treating conditions associated with corneal transplantation
US08/557,287 1995-11-14
PCT/US1996/018416 WO1997017989A1 (en) 1995-11-14 1996-11-12 Bactericidal/permeability increasing protein (bpi) for treating conditions associated with corneal transplantation

Publications (2)

Publication Number Publication Date
CA2235625A1 CA2235625A1 (en) 1997-05-22
CA2235625C true CA2235625C (en) 2002-03-12

Family

ID=24224798

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002235625A Expired - Fee Related CA2235625C (en) 1995-11-14 1996-11-12 Bactericidal/permeability increasing protein (bpi) for treating conditions associated with corneal transplantation

Country Status (6)

Country Link
US (1) US5686414A (https=)
EP (1) EP0861087A1 (https=)
JP (1) JP2002515858A (https=)
AU (1) AU730303B2 (https=)
CA (1) CA2235625C (https=)
WO (1) WO1997017989A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
WO1997004008A1 (en) * 1995-07-20 1997-02-06 Xoma Corporation Anti-fungal peptides
WO1997017990A1 (en) * 1995-11-14 1997-05-22 Xoma Corporation Bactericidal permeability increasing protein (bpi) for treating conditions associated with corneal injury
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
PT2301583E (pt) * 2000-12-19 2012-12-06 Res Dev Foundation Transferência de genes mediada por vetor de lentivírus
SE523017C2 (sv) 2001-03-30 2004-03-23 Aga Ab Publ Spolfluidkomposition
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
DE602005007928D1 (de) * 2004-11-08 2008-08-14 Unilever Nv Flüssiges waschmittel
FR2882930B1 (fr) * 2005-03-09 2009-03-27 Walid Katib Nouvelles compositions ophtalmologiques et leur mode d'utilisation
MX389960B (es) 2009-10-12 2025-03-20 Boehringer Ingelheim Vetmedica Gmbh Recipientes para composiciones que comprenden meloxicam.
CA2791805A1 (en) 2010-03-03 2011-09-09 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
US8523942B2 (en) 2011-05-17 2013-09-03 James Stuart Cumming Variable focus intraocular lens
US9295544B2 (en) 2012-06-05 2016-03-29 James Stuart Cumming Intraocular lens
US10736732B2 (en) 2010-06-21 2020-08-11 James Stuart Cumming Intraocular lens with longitudinally rigid plate haptic
US9295545B2 (en) 2012-06-05 2016-03-29 James Stuart Cumming Intraocular lens
US9585745B2 (en) 2010-06-21 2017-03-07 James Stuart Cumming Foldable intraocular lens with rigid haptics
US9918830B2 (en) 2010-06-21 2018-03-20 James Stuart Cumming Foldable intraocular lens with rigid haptics
US9351825B2 (en) 2013-12-30 2016-05-31 James Stuart Cumming Semi-flexible posteriorly vaulted acrylic intraocular lens for the treatment of presbyopia
US9295546B2 (en) 2013-09-24 2016-03-29 James Stuart Cumming Anterior capsule deflector ridge
LT2788472T (lt) 2011-12-06 2019-04-10 Astellas Institute For Regenerative Medicine Kryptingos diferenciacijos būdas, skirtas ragenos endotelio ląstelių gamybai
US20140155871A1 (en) * 2012-05-10 2014-06-05 James Stuart Cumming Method for preparing corneal donor tissue for refractive eye surgery utilizing the femtosecond laser
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
US9615916B2 (en) 2013-12-30 2017-04-11 James Stuart Cumming Intraocular lens
US20240368541A1 (en) 2021-05-03 2024-11-07 Astellas Institute For Regenerative Medicine Methods of generating mature corneal endothelial cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242902A (en) * 1989-09-06 1993-09-07 The Regents Of The University Of California Defensin peptide compositions and methods for their use
PT682524E (pt) * 1993-02-02 2002-03-28 Xoma Technology Ltd Composicoes farmaceuticas que contem a proteina bactericida indutora da permeabilidade e um agente tensioactivo
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5912228A (en) * 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
WO1997017990A1 (en) * 1995-11-14 1997-05-22 Xoma Corporation Bactericidal permeability increasing protein (bpi) for treating conditions associated with corneal injury

Also Published As

Publication number Publication date
EP0861087A1 (en) 1998-09-02
WO1997017989A1 (en) 1997-05-22
CA2235625A1 (en) 1997-05-22
AU7736196A (en) 1997-06-05
AU730303B2 (en) 2001-03-01
US5686414A (en) 1997-11-11
JP2002515858A (ja) 2002-05-28

Similar Documents

Publication Publication Date Title
CA2235625C (en) Bactericidal/permeability increasing protein (bpi) for treating conditions associated with corneal transplantation
US6849598B1 (en) Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
DE69527195T2 (de) Anti gram positive bakterielle verfahren und mittel
Moore et al. Acanthamoeba keratitis associated with soft contact lenses
Wilson Analysis of the keratocyte apoptosis, keratocyte proliferation, and myofibroblast transformation responses after photorefractive keratectomy and laser in situ keratomileusis
US5221664A (en) Composition and treatment with biologically active peptides and toxic cations
DE69526216T2 (de) Antifungaleverfahren und mitteln
US7893027B2 (en) Treatment of ocular wounds and ulcers
Gee et al. Extracapsular cataract extraction in Fuchs' heterochromic iridocyclitis
CA2235626C (en) Bactericidal permeability increasing protein (bpi) for treating conditions associated with corneal injury
WO2016060917A2 (en) Formulations for histatin therapeutics
US5208220A (en) Composition and treatment with biologically active peptides and antibiotics which inhibit DNA gyrase
Peyman et al. Vitrectomy in exogenous Candida endophthalmitis
Borhani et al. Use of vancomycin in vitrectomy infusion solution and evaluation of retinal toxicity
Chen et al. Endophthalmitis caused by Stenotrophomonas maltophilia
Schwartz et al. Posttraumatic phycomycosis of the anterior segment
KR102023827B1 (ko) 안구 건조증 질환의 치료 및/또는 예방을 위한 짧은 합성 펩티드의 용도
CN101300022A (zh) 抗真菌肽和其使用方法
Ghiselli et al. Therapeutic efficacy of the polymyxin-like peptide ranalexin in an experimental model of endotoxemia
WO2000071149A2 (en) Therapeutic uses of bpi protein products in humans with otitis media with effusion
Kumar et al. Intravitreal pefloxacin therapy in postoperative endophthalmitis
Verbraeken Endophthalmitis after lens extraction
US20020119918A1 (en) Therapeutic uses of n-terminal bpi protein products in anca-positive patients
Barza Experimental occular infections
Shahsavari et al. Shiva-1: in vitro and in vivo tests of the effects of a novel, synthetic, lytic peptide on ocular cells

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed